Erlotinib 150mg Tablet Erlotib
Trade Name: Erlotib
Manufacturer: Intas Pharmaceuticals Ltd
What is Erlotinib 150mg Tablet?
Erlotinib 150mg Tablet is used in the treatment of non-little cell cellular breakdown in the lungs as well as pancreatic disease. It is available in tablet form.
How Erlotib is used?
Erlotib should be taken on an empty stomach, or it should be taken one hour before or two hours after a meal if it is required. You should continue to accept it as long as your primary care physician requests that you do so. The length of treatment varies depending on your needs and how you respond to the treatments. You should take it exactly as directed by your primary care physician. It is possible to experience severe incidental effects if you misinterpret it or take too much of it. It may take a few weeks or months for you to notice or feel the benefits of taking this medication, so don’t stop taking it unless your primary care physician instructs you to do so.
Common Side effects of Erlotib 150mg Tablet:
Some of the most well-known side effects of this medicine include nausea, vomiting, weakness, rash, and weight loss. If you experience severe constipation while taking this medicine, drink plenty of water and contact your primary care physician right away. When going outside, use protective clothing or use sunscreen because it makes you more vulnerable to sunlight. It is best to get medical advice if you have a mouth ulcer, changes in your vision, or breathing problems. Routine liver function testing may be recommended by your primary care physician during your therapy with this drug. To know more click here.
Uses of Erlotinib:
Erlotinib is a drug used to treat non-small cell lung cancer that has spread to nearby tissues or other parts of the body in patients who have failed to respond to at least one earlier chemotherapy treatment.
We are a Global wholesaler and exporter from India and operate in more than 5 countries like Oman, Qatar, UAE, Saudi, Myanmar. If you’re looking for a different product or brand, click here.